TICKERNERD
Menu
TNDMTNDMHealthcare · Medical Devices

TNDM Stock Forecast: Tandem Diabetes Care, Inc. Price Predictions for 2026-2027

Last close, 21 Sept 2026
$18
+4.51% on the day

The 24 Wall Street analysts covering Tandem Diabetes Care, Inc. hold a median 12-month price target of $27 — +50.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 19 Sept 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$1.2B
Ticker Nerd rank
70 / 100
Median analyst target
$27
Analysts covering
24
Revenue$254.6M+5.8% y/y
Operating income−$13.8M
Net income−$21.2M
Free cash flow−$38.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.9%
1M
−21.0%
YTD
−19.8%
1Y
+40.3%
From 52W high
−37.6%
From 52W low
+49.5%
$12
$28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TNDM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tandem Diabetes Care, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
70 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
89
Quality
83
Value
81
Volatility
73
Momentum
63
Revisions
54
Accruals
46
Size
42
Issuance
16

Growth (89): Sales and profits are climbing, and climbing faster than before.

Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TNDM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TNDM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26TNDMHigh $50Median $27Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says24 analysts
13 Buy11 Hold0 Sell
Low $18Median $27High $50

The green dot is the last close — the median target sits +50.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
21 Aug 2026William BlairInitiatesOutperform—
7 Aug 2026CitigroupMaintainsNeutral—
7 Aug 2026CitigroupMaintainsNeutral$17 → $21
7 Aug 2026RBC CapitalMaintainsOutperform—
7 Aug 2026RBC CapitalMaintainsOutperform$30 → $26
28 July 2026UBSAssumesNeutral$22 → $18
15 July 2026MizuhoMaintainsNeutral$24 → $20
15 July 2026MizuhoMaintainsNeutral—
23 June 2026Deutsche BankInitiatesHold$16
23 June 2026Deutsche BankInitiatesHold—
1 June 2026Wells FargoUpgradeOverweight—
28 May 2026CitigroupMaintainsNeutral—
18 May 2026B of A SecuritiesMaintainsNeutral—
12 May 2026BenchmarkInitiatesHold—
11 May 2026BarclaysMaintainsOverweight—
11 May 2026Truist SecuritiesReiteratesBuy—
20 Apr 2026TD CowenMaintainsBuy—
9 Apr 2026Goldman SachsMaintainsNeutral—
19 Mar 2026Truist SecuritiesUpgradeBuy—
17 Mar 2026Piper SandlerUpgradeOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TNDM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TNDM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 21 Sept 2026, Tandem Diabetes Care, Inc. returned +40.3% against +15.7% for the S&P 500, dividends included.

TNDM vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Oct 25Jan 26Apr 26Jul 26TNDMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TNDM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
11
Analysts cutting
7
Fundamentals

Tandem Diabetes Care, Inc. (TNDM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.5×

Cheaper than 90% of US stocks

Price / sales
1.1×

Cheaper than 66% of US stocks

Price / book
9.0×

Cheaper than 10% of US stocks

EV / EBITDA
−58.2×

Cheaper than 95% of US stocks

Growth & margins
Revenue growth (YoY)
5.8%

Higher than 41% of US stocks

Earnings growth (YoY)
—
Gross margin
56.9%

Higher than 70% of US stocks

Operating margin
−5.4%

Higher than 27% of US stocks

Net margin
−6.1%

Higher than 23% of US stocks

Returns & dividend
Return on equity
−48.0%

Higher than 22% of US stocks

Return on assets
−2.6%

Higher than 35% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Tandem Diabetes Care, Inc. (TNDM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tandem Diabetes Care, Inc. has a market value of $1.2B and an enterprise value of $1.5B.

  • Revenue in the twelve months to 30 June 2026: $1.0B. The latest quarter grew 5.8% year on year.

  • Net income over the same four quarters: −$63.3M, a −6.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.93.

  • Free cash flow in the twelve months to 30 June 2026: −$61.7M.

  • Shares outstanding: 69.5M.

  • Trailing P/E: −5.5×; forward P/E: 98.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Tandem Diabetes Care, Inc. employs 2,500 people — $417K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

TNDM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
TNDMTandem Diabetes Care, Inc.$1.2B
70
IARTIntegra LifeSciences Holdings Corp.$1.2B
87
BBNXBeta Bionics, Inc.$1.2B
40
AORTArtivion, Inc.$1.1B
41
PRCTPROCEPT BioRobotics Corp.$1.1B
38
BVSBioventus, Inc.$1.1B
98
IRMDIRadimed Corp.$1.1B
89

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Tandem Diabetes Care, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TNDM news & analysis

Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?

Zacks Investment Research · 17 Sept 2026positive

Tandem Diabetes Care (TNDM) was a big mover in the last session on higher-than-average trading volume, with its stock rising 7.7%. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Why it matters — A TNDM watcher would care because the earnings estimate revision trend and strong trading moves may signal continued momentum in the near term.

Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now

Zacks Investment Research · 9 Sept 2026neutral

Zacks Investment Research published an article recommending investors retain Tandem Diabetes stock, citing the company's expanding insulin pump lineup and pay-as-you-go model as supporting growth prospects. The article also notes that macro and competitive pressures remain for the company.

Why it matters — TNDM watchers would care because the article outlines the key growth drivers behind the pump maker's prospects while acknowledging the ongoing macro and competitive headwinds that could affect performance.

Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics

Benzinga · 21 Aug 2026positive

William Blair initiated coverage on Tandem Diabetes Care and Beta Bionics, noting both companies are advancing initiatives to compete in faster-growing segments of the insulin pump market.

Why it matters — The analyst initiation highlights Tandem's efforts in faster-growing insulin pump segments, which could draw attention to its competitive positioning.

Tandem Diabetes Care Maps Growth Plan With Pharmacy Shift and Tubeless Mobi

MarketBeat · 18 Aug 2026positive

Tandem Diabetes Care outlined its growth plans to expand insulin pump adoption, including a shift to pharmacy distribution in the U.S., direct sales in additional international markets, and upcoming product launches such as a tubeless version of its Tandem Mobi pump.

Why it matters — A TNDM watcher would care because these distribution changes and the planned tubeless Mobi launch could influence the company's market reach and adoption of its insulin pumps.

TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up

Zacks Investment Research · 12 Aug 2026positive

Tandem Diabetes shares rose 19.1% after reporting a narrower-than-expected Q2 loss, supported by higher pump shipments and a 57% gross margin, which offset a slight revenue miss versus expectations.

Why it matters — The quarter's narrower loss and strong gross margin, despite the revenue miss, point to improving profitability from core pump sales that TNDM watchers would track.

FAQ

Frequently asked questions about TNDM stock

What is the TNDM stock price forecast for 2026-2027?

The 24 Wall Street analysts covering Tandem Diabetes Care, Inc. have a median 12-month price target of $27, with estimates ranging from $18 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TNDM stock a buy right now?

Of the 24 analysts covering Tandem Diabetes Care, Inc., 13 rate it a Buy, 11 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tandem Diabetes Care, Inc. 70 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TNDM?

As at 19 Sept 2026, Tandem Diabetes Care, Inc. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (89 of 100).

Will TNDM stock go up?

No one can know that. What the data says: the median 12-month target from 24 analysts implies +50.3% from the last close, and Ticker Nerd's factor model ranks Tandem Diabetes Care, Inc. 70 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TNDM stock forecast for 2030?

No analyst covering Tandem Diabetes Care, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TNDM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $50 over the next 12 months.

How has TNDM stock performed over the past year?

Tandem Diabetes Care, Inc. returned +40.3% over the 12 months to 21 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tandem Diabetes Care, Inc. do?

Tandem Diabetes Care, Inc. is a medical device company focused on diabetes management technology.

What is the latest news on TNDM?

The most recent item we track (Zacks Investment Research, 17 Sept 2026): "Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?". Tandem Diabetes Care (TNDM) was a big mover in the last session on higher-than-average trading volume, with its stock rising 7.7%. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Company

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. is a medical device company focused on diabetes management technology. Tandem Diabetes Care develops and commercializes automated insulin delivery systems designed for people living with insulin-dependent diabetes, with its current product portfolio centered on the t:slim X2 insulin pump and the Tandem Mobi insulin pump. The company’s systems integrate Control-IQ technology and work with compatible continuous glucose monitors to help automate insulin delivery and support day-to-day glucose management. Tandem Diabetes Care also provides related products and services such as infusion sets, cartridges, software updates, data management tools, and mobile applications that support pump users and healthcare providers. Its offerings are used in the United States and in international markets, positioning the company as a specialized player in the broader diabetes care and medical technology sector.

CEO Mr. John F. Sheridan · 2,500 employees · United States · https://www.tandemdiabetes.com